Notably, loss of Clec9a completely reversed the relative resistance of sGSN-deficient mice to MCA-205 and B16F10 LA-OVA-mCherry tumors (Figures 5D and 5E) but did not impact growth of the same cancers in sGSN-sufficient hosts (Figures S4K and S4L). This evidence concerns the gene CLEC9A and cancer.